1 – 250 of 317
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Low bleeding rates after intramuscular Covid-19 vaccination in patients with haemophilia and von Willebrand disease : Outcome data from the Swedish haemophilia registry
2024) In Haemophilia(
- Contribution to journal › Debate/Note/Editorial
-
Mark
International Prophylaxis Study Group (IPSG) haemophilia joint MRI scale version 2.0
(
- Contribution to journal › Letter
-
Mark
Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B
2024) In Haemophilia(
- Contribution to journal › Article
-
Mark
Primary prophylaxis implementation and long-term joint outcomes in Swedish haemophilia A patients
2024) In Haemophilia(
- Contribution to journal › Article
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
- 2023
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Real-world prophylactic usage of recombinant factor IX Fc in Sweden : A report from the Swedish National Registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
(
- Contribution to journal › Article
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article
-
Mark
Methods for anti-factor VIII antibody levels in haemophilia A patients-validation of a multiplec immunoassay and comparability with assays measuring non-neutralising and neutralising antibodies (inhibitors)
(
- Contribution to journal › Article
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia : A review of the literature
(
- Contribution to journal › Scientific review
-
Mark
Haemophilia A and B - evaluation of the Swedish prophylactic regimen by magnetic resonance imaging
(
- Contribution to journal › Article
-
Mark
Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children : Systematic and targeted literature reviews
(
- Contribution to journal › Scientific review
-
Mark
Primary prophylaxis in children with severe haemophilia A and B-Implementation over the last 20 years as illustrated in real-world data in the PedNet cohorts
(
- Contribution to journal › Article
-
Mark
Dilemmas on emicizumab in children with haemophilia A : A survey of strategies from PedNet centres
(
- Contribution to journal › Article
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
(
- Contribution to journal › Scientific review
- 2022
-
Mark
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B : Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires
(
- Contribution to journal › Article
-
Mark
Platelet function testing : Current practice among clinical centres in Northern Europe
(
- Contribution to journal › Article
-
Mark
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins : Real-world experience in the Nordic countries
(
- Contribution to journal › Article
-
Mark
Long-term joint outcomes in adolescents with moderate or severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Sixth Åland Island Conference on von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Autologous cell therapy - A new concept to eradicate inhibitors in haemophilia
(
- Contribution to journal › Letter
-
Mark
Alternative payment models for durable and potentially curative therapies : The case of gene therapy for haemophilia A
(
- Contribution to journal › Article
-
Mark
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81–8973
(
- Contribution to journal › Article
-
Mark
Pain, depression and anxiety in people with haemophilia from three Nordic countries : Cross-sectional survey data from the MIND study
(
- Contribution to journal › Article
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
-
Mark
Bone mineral density in haemophilia – a multicentre study evaluating the impact of different replacement regimens
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
(
- Contribution to journal › Article
- 2021
-
Mark
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa
(
- Contribution to journal › Article
-
Mark
Recombinant FVIIa in elective non-orthopaedic surgery of adults with haemophilia and inhibitors : A systematic literature review
(
- Contribution to journal › Scientific review
-
Mark
Treatment outcomes in persons with severe haemophilia B in the Nordic region : The B-NORD study
(
- Contribution to journal › Article
-
Mark
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A
(
- Contribution to journal › Article
-
Mark
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study
(
- Contribution to journal › Article
-
Mark
Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays
(
- Contribution to journal › Article
-
Mark
Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors
(
- Contribution to journal › Scientific review
-
Mark
Collagen remodelling and plasma ascorbic acid levels in patients suspected of inherited bleeding disorders harbouring germline variants in collagen‐related genes
(
- Contribution to journal › Article
-
Mark
In response to WFH guidelines for the management of haemophilia, 3rd edition : Is there a difference between extended-half-life FVIII products or not?
(
- Contribution to journal › Letter
-
Mark
Real-world prophylactic usage of recombinant factor VIII Fc in Sweden : A report from the Swedish national registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation
(
- Contribution to journal › Article
-
Mark
The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
(
- Contribution to journal › Article
-
Mark
Identification of F8 rearrangements in carrier and non-carrier mothers of haemophilia A patients
(
- Contribution to journal › Letter
-
Mark
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
(
- Contribution to journal › Article
- 2020
-
Mark
Registries and databases : A European perspective
(
- Contribution to journal › Article
-
Mark
Genetic screening of children with suspected inherited bleeding disorders
(
- Contribution to journal › Article
-
Mark
Achieving the unimaginable : Health equity in haemophilia
(
- Contribution to journal › Scientific review
-
Mark
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study
(
- Contribution to journal › Article
-
Mark
Critical appraisal of the International Prophylaxis Study Group magnetic resonance image scale for evaluating haemophilic arthropathy
(
- Contribution to journal › Article
-
Mark
WFH Guidelines for the Management of Hemophilia, 3rd edition
(
- Contribution to journal › Article
- 2019
-
Mark
Cardiovascular disease-related hospitalization and mortality among persons with von Willebrand disease : A nationwide register study in Sweden
(
- Contribution to journal › Article
-
Mark
Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia : A comparison between intermediate- and high-dose prophylaxis
(
- Contribution to journal › Article
-
Mark
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A : Combined analysis of three studies
(
- Contribution to journal › Article
-
Mark
Coagulation factor VIII is vital for increasing global coagulation after physical exercise
(
- Contribution to journal › Article
-
Mark
Evaluation of a standardized protocol for thrombin generation using the calibrated automated thrombogram : A Nordic study
(
- Contribution to journal › Article
-
Mark
Moderate haemophilia in focus
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Joint comorbidities among Swedish carriers of haemophilia : A register-based cohort study over 22 years
(
- Contribution to journal › Article
- 2018
-
Mark
Immune tolerance induction : What have we learned over time?
(
- Contribution to journal › Scientific review
-
Mark
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII
(
- Contribution to journal › Article
-
Mark
Replacement therapy during surgery in von Willebrand disease needs personalization
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The role of the laboratory in diagnosis and management of inhibitory antibodies in haemophilia
(
- Contribution to journal › Article
-
Mark
Evaluation of prophylactic therapy in haemophilia with global coagulation tests
(
- Contribution to journal › Letter
-
Mark
Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis : Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network
(
- Contribution to journal › Article
-
Mark
Fifth Åland Island conference on von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Defining extended half-life rFVIII-A critical review of the evidence
(
- Contribution to journal › Article
- 2017
-
Mark
European retrospective study of real-life haemophilia treatment
(
- Contribution to journal › Article
-
Mark
Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics
(
- Contribution to journal › Article
-
Mark
The impact of clinical practice on the outcome of central venous access devices in children with haemophilia
(
- Contribution to journal › Article
-
Mark
Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy : The Malmö experience
(
- Contribution to journal › Article
-
Mark
Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits : A two-centre study
(
- Contribution to journal › Article
-
Mark
The association between health utility and joint status among people with severe haemophilia A : findings from the KAPPA register
(
- Contribution to journal › Article
-
Mark
Comparative burden of arthropathy in mild haemophilia : a register-based study in Sweden
(
- Contribution to journal › Article
-
Mark
Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B
(
- Contribution to journal › Article
-
Mark
Plasma products do not solve the inhibitor problem
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Low agreement between fresh and frozen-thawed platelet-rich plasma in the calibrated automated thrombogram assay
(
- Contribution to journal › Article
-
Mark
Preference-based valuation of treatment attributes in haemophilia A using web survey
(
- Contribution to journal › Article
- 2016
-
Mark
BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
(
- Contribution to journal › Article
-
Mark
Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
(
- Contribution to journal › Article
-
Mark
Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
2016) In Haemophilia(
- Contribution to journal › Article
-
Mark
Evaluating outcome of prophylaxis in haemophilia: objective and self-reported instruments should be combined.
2016) In Haemophilia(
- Contribution to journal › Article
-
Mark
Potential biomarkers of haemophilic arthropathy : correlations with compatible additive magnetic resonance imaging scores
(
- Contribution to journal › Article
-
Mark
SPINART study : validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data
(
- Contribution to journal › Article
-
Mark
Hypertension, haematuria and renal functioning in haemophilia - a cross-sectional study in Europe
(
- Contribution to journal › Article
-
Mark
Haemophilia treatment in 2030
(
- Contribution to journal › Article
-
Mark
Inhibitor development in previously untreated patients with severe haemophilia A : a nationwide multicentre study in Finland
(
- Contribution to journal › Article
-
Mark
Phenotype and genotype comparisons in carriers of haemophilia A
(
- Contribution to journal › Article
- 2015
-
Mark
Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.
(
- Contribution to journal › Article
-
Mark
Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand
(
- Contribution to journal › Article
-
Mark
The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Association between bleeding tendency and health-related quality of life in carriers of moderate and severe haemophilia.
(
- Contribution to journal › Article
-
Mark
Bleeding phenotype in carriers of haemophilia A does not correlate with thrombin generation
(
- Contribution to journal › Letter
-
Mark
Acute effects of exercise on specific and global coagulation parameters in severe haemophilia A.
(
- Contribution to journal › Letter
-
Mark
How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access
(
- Contribution to journal › Article
-
Mark
Mutation analysis of Swedish haemophilia B families - high frequency of unique mutations.
2015) In Haemophilia(
- Contribution to journal › Article
- 2014
-
Mark
A longitudinal study of family structure in Swedish persons with haemophilia.
(
- Contribution to journal › Article
-
Mark
Prenatal diagnosis of haemophilia in Sweden now more commonly used for psychological preparation than termination of pregnancy.
(
- Contribution to journal › Article
-
Mark
Laboratory aspects of von Willebrand disease : test repertoire and options for activity assays and genetic analysis
(
- Contribution to journal › Scientific review
-
Mark
A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
(
- Contribution to journal › Letter
-
Mark
Managing Haemophilia for Life: 4th Haemophilia Global Summit
(
- Contribution to journal › Scientific review
-
Mark
Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry
(
- Contribution to journal › Article
-
Mark
Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?
(
- Contribution to journal › Article
-
Mark
Similar bleeding phenotype in young children with haemophilia A or B : A cohort study
(
- Contribution to journal › Article
- 2013
-
Mark
Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden.
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Novel coagulation factor concentrates: Issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients.
(
- Contribution to journal › Scientific review
-
Mark
Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)
(
- Contribution to journal › Article
-
Mark
History of prophylaxis.
(
- Contribution to journal › Article
-
Mark
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Article
-
Mark
Progressive improvement in wound healing with increased therapy in haemophilia B mice
(
- Contribution to journal › Article
-
Mark
Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study
(
- Contribution to journal › Article
-
Mark
Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.
(
- Contribution to journal › Article
- 2012
-
Mark
Differences between developed and developing countries in paediatric care in haemophilia
(
- Contribution to journal › Article
-
Mark
Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders
(
- Contribution to journal › Article
-
Mark
Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors
(
- Contribution to journal › Letter
-
Mark
A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
(
- Contribution to journal › Article
-
Mark
Quality of life in adult patients with haemophilia - a single centre experience from Sweden.
(
- Contribution to journal › Article
-
Mark
Management of bleeding disorders in children
(
- Contribution to journal › Scientific review
-
Mark
Haemophilia Care in Europe: the ESCHQoL study
(
- Contribution to journal › Article
-
Mark
Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
(
- Contribution to journal › Article
-
Mark
The Arosenius Fund.
(
- Contribution to journal › Article
-
Mark
An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group.
(
- Contribution to journal › Article
-
Mark
Clinical trial design in haemophilia.
(
- Contribution to journal › Article
-
Mark
Malignant disease in the haemophilic population: moving towards a management consensus?
(
- Contribution to journal › Article
-
Mark
Prevention and prediction of inhibitor risk.
(
- Contribution to journal › Article
-
Mark
Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.
(
- Contribution to journal › Article
-
Mark
Investigation of disease-associated factors in haemophilia A patients without detectable mutations.
(
- Contribution to journal › Article
-
Mark
Activated factor VII: my story.
(
- Contribution to journal › Article
-
Mark
Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.
2012) In Haemophilia(
- Contribution to journal › Article
-
Mark
The international factor IX treatment network survey.
(
- Contribution to journal › Letter
-
Mark
Optimizing joint function : new knowledge and novel tools and treatments
(
- Contribution to journal › Article
-
Mark
von Willebrand's disease: a report from a meeting in the Åland islands.
(
- Contribution to journal › Article
-
Mark
Models of prophylaxis.
(
- Contribution to journal › Article
- 2011
-
Mark
Joint protection in haemophilia
(
- Contribution to journal › Article
-
Mark
Osteoporosis: a real problem in haemophilia?
(
- Contribution to journal › Published meeting abstract
-
Mark
The pro-FEIBA study: prophylactic dosing of Factor Eight Inhibitor Bypassing Activity (FEIBA) reduces bleeding frequency in haemophilia a patients with inhibitors
(
- Contribution to journal › Published meeting abstract
-
Mark
The international factor IX treatment network survey
(
- Contribution to journal › Published meeting abstract
-
Mark
The need for speed in the management of haemophilia patients with inhibitors
(
- Contribution to journal › Article
-
Mark
Bone density and health-related quality of life in adult patients with severe haemophilia.
(
- Contribution to journal › Article
-
Mark
Delivery of a severe haemophilia foetus - vaginal delivery
(
- Contribution to journal › Published meeting abstract
-
Mark
Optimizing patient therapy - optimal dosing: when is enough enough?
(
- Contribution to journal › Article
-
Mark
Monitoring rFVIIa 90 μg kg(-1) dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
(
- Contribution to journal › Article
-
Mark
Haematuria and hypertension in haemophilia - the H3 study
(
- Contribution to journal › Published meeting abstract
-
Mark
A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
(
- Contribution to journal › Article
-
Mark
Importance of rapid bleeding control in haemophilia complicated by inhibitors.
(
- Contribution to journal › Article
-
Mark
The Swedish version of the Haemophilia Activity List.
(
- Contribution to journal › Article
-
Mark
Recommendations for assessment, monitoring and follow-up of patients with haemophilia.
2011) In Haemophilia(
- Contribution to journal › Article
-
Mark
First 20 years with recombinant FVIIa (NovoSeven).
(
- Contribution to journal › Article
-
Mark
Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition.
(
- Contribution to journal › Article
- 2010
-
Mark
FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations
(
- Contribution to journal › Article
-
Mark
The combination of Octaplex (R) and Octanate (R) restores thrombin generation capacity in FVIII inhibitor plasma in-vitro
(
- Contribution to journal › Published meeting abstract
-
Mark
Comparison of several automated VWF:RCo assays for monitoring of patients treated with VWF/FVIII concentrates: improved performance with a new modified method
(
- Contribution to journal › Published meeting abstract
-
Mark
The necessity of having FVIII in VWF concentrates
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.400-400(
- Contribution to journal › Published meeting abstract
-
Mark
A prospective, randomized, and crossover study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors (Pro-FEIBA): subject demographics and safety data
2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.31-31(
- Contribution to journal › Published meeting abstract
-
Mark
Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies
(
- Contribution to journal › Scientific review
-
Mark
A randomized clinical trial on prophylaxis vs. episodic treatment in children with haemophilia A: the ESPRIT study
2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.29-30(
- Contribution to journal › Published meeting abstract
-
Mark
Hemophilia A patients without detectable mutations - investigation of disease-associated factors
(
- Contribution to journal › Published meeting abstract
-
Mark
Management of bleedings in carriers
(
- Contribution to journal › Published meeting abstract
-
Mark
A retrospective study: of Octaplex (R) in the treatment of bleeding in patients with haemophilia A complicated by inhibitors
(
- Contribution to journal › Published meeting abstract
-
Mark
Von Willebrand disease prophylaxis network
(
- Contribution to journal › Published meeting abstract
-
Mark
European Initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) - a prospective study
(
- Contribution to journal › Published meeting abstract
-
Mark
Why is the frequency of inhibitors increasing among Swedish children with severe hemophilia A?
(
- Contribution to journal › Published meeting abstract
-
Mark
Clinical issues in inhibitors
(
- Contribution to journal › Scientific review
-
Mark
Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay (VWF:RCo) using a novel automated assay protocol
(
- Contribution to journal › Published meeting abstract
-
Mark
The role of prophylaxis in bleeding disorders
(
- Contribution to journal › Scientific review
-
Mark
Prophylaxis in von Willebrand disease
(
- Contribution to journal › Published meeting abstract
-
Mark
Scoring systems for MRI evaluations of hemophilic joints
(
- Contribution to journal › Published meeting abstract
-
Mark
European initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) - a prospective study
(
- Contribution to journal › Published meeting abstract
-
Mark
Prophylaxis in hemophilia
(
- Contribution to journal › Published meeting abstract
-
Mark
Assessment of health-related quality of life in patients with severe haemophilia with reduced bone density
(
- Contribution to journal › Published meeting abstract
-
Mark
Factor VIII light chain mutations and cysteine substitutions predispose for inhibitor development in mild and moderate haemophilia A: first results from the INSIGHT study
(
- Contribution to journal › Published meeting abstract
-
Mark
Mild haemophilia in Sweden
(
- Contribution to journal › Published meeting abstract
-
Mark
Differential response to bypassing agents
(
- Contribution to journal › Published meeting abstract
-
Mark
The international factor IX treatment network survey
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403(
- Contribution to journal › Published meeting abstract
-
Mark
Use and limitations of APTT as a screening test for mild bleeding disorders
(
- Contribution to journal › Published meeting abstract
-
Mark
Quality of life in parents of children with haemophilia - results of the ESCHQoL study
(
- Contribution to journal › Published meeting abstract
-
Mark
Network activities were initiated in December, 2009, and will extend over the next five years. von Willebrand disease prophylaxis network
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403(
- Contribution to journal › Published meeting abstract
-
Mark
Influence of the pre-analytical specimen storage conditions on thrombin generation assay
2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.45-45(
- Contribution to journal › Published meeting abstract
-
Mark
F8 haplotype and recombinant product use in the Hemophilia Inhibitor Genetics Study (HIGS)
(
- Contribution to journal › Published meeting abstract
-
Mark
The optimal mode of delivery for the haemophilia carrier expecting an affected infant is vaginal delivery.
(
- Contribution to journal › Article
-
Mark
Reply to 'Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors' (Haemophilia 2009; 15: 3-10).
(
- Contribution to journal › Article
-
Mark
Inhibitor development: patient-determined risk factors.
(
- Contribution to journal › Article
-
Mark
Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.
(
- Contribution to journal › Article
-
Mark
Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis.
(
- Contribution to journal › Article
-
Mark
Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A.
(
- Contribution to journal › Article
-
Mark
Knowledge of disease and adherence in adult patients with haemophilia.
(
- Contribution to journal › Article
-
Mark
Considerations in the laboratory assessment of haemostasis
(
- Contribution to journal › Scientific review
- 2009
-
Mark
Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
(
- Contribution to journal › Article
-
Mark
Cumulative incidence of inhibitors: it is influenced by type of replacement therapy in previously treated boys with severe haemophilia A. No
(
- Contribution to journal › Published meeting abstract
-
Mark
The plasma concentration of activated protein C appears normal in patients with haemophilia
(
- Contribution to journal › Article
-
Mark
Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs
(
- Contribution to journal › Scientific review
-
Mark
Improved automated VWF:RCo assay for VWF/FVIII concentrates and plasma samples by adjustment of assay reagents, composition and performance parameters
(
- Contribution to journal › Published meeting abstract
-
Mark
The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic
(
- Contribution to journal › Article
-
Mark
Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
(
- Contribution to journal › Article
-
Mark
European curriculum for thrombosis and haemostasis.
(
- Contribution to journal › Article
-
Mark
Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density.
(
- Contribution to journal › Article
-
Mark
Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?
(
- Contribution to journal › Article
-
Mark
Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
-
Mark
Measuring patient-reported outcomes in haemophilia clinical research
(
- Contribution to journal › Scientific review
- 2008
-
Mark
A 10-year, randomized, clinical trial on prophylaxis vs. on-demand treatment in children with haemophilia A: the E.S.P.R.I.T. study
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.99-99(
- Contribution to journal › Published meeting abstract
-
Mark
High purity, double virus-inactivated VWF/FVIII concentrate in long term prophylaxis of von Willebrand disease - experience from prospective clinical trials and German post-licensure surveillance
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.12-12(
- Contribution to journal › Published meeting abstract
-
Mark
VWF : RCo assays using automated systems for VWF/FVIII concentrates require adjustment of assay reagents, composition and performance parameters
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.116-116(
- Contribution to journal › Published meeting abstract
-
Mark
A review of health economic studies in hemophilia prophylaxis: a collaboration of the economics expert working group of the International Prophylaxis Study Group (IPSG)
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.133-133(
- Contribution to journal › Published meeting abstract
-
Mark
Digital scoring of haemophilic arthropathy using radiographs: is it feasible?
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.73-73(
- Contribution to journal › Published meeting abstract
-
Mark
Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors
(
- Contribution to journal › Article
-
Mark
The Swedish version of hemophilia activity list, HAL
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.74-74(
- Contribution to journal › Published meeting abstract
-
Mark
Quality of life in haemophilia carriers - preliminary results of the ESCHQoL study
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.150-150(
- Contribution to journal › Published meeting abstract
-
Mark
Thrombin generation assay: a useful tool in the management of haemophilia A patients?
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.26-26(
- Contribution to journal › Published meeting abstract
-
Mark
European principles of haemophilia care
(
- Contribution to journal › Article
-
Mark
Genetic aspects of inhibitor development
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.21-21(
- Contribution to journal › Published meeting abstract
-
Mark
von Willebrand disease update: diagnostic and treatment dilemmas
(
- Contribution to journal › Article
-
Mark
Different approaches to primary prophylaxis in boys with severe hemophilia A
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.142-142(
- Contribution to journal › Published meeting abstract
-
Mark
The importance of maintaining FVIII through levels above 1% during prophylactic treatment of hemophilia A: using license study databases to answer key medical questions
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.58-58(
- Contribution to journal › Published meeting abstract
-
Mark
Bone density in hemophilia
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.79-79(
- Contribution to journal › Published meeting abstract
-
Mark
Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
(
- Contribution to journal › Article
-
Mark
Digital scoring of haemophilic arthropathy using radiographs is feasible
(
- Contribution to journal › Article
-
Mark
New risk factors for inhibitor development
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.43-43(
- Contribution to journal › Published meeting abstract
-
Mark
Female haemophilia A caused by skewed X inactivation
(
- Contribution to journal › Letter
-
Mark
Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?
(
- Contribution to journal › Article
-
Mark
Management of carriers and babies with haemophilia
(
- Contribution to journal › Article
-
Mark
Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors
(
- Contribution to journal › Article
-
Mark
Being a carrier of haemophilia - how does it influence quality of life?
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.152-153(
- Contribution to journal › Published meeting abstract
-
Mark
Genetic aspects and research development in haemostasis
(
- Contribution to journal › Article
-
Mark
Patients' and their family members' understanding of the genetics of type 1 von Willebrand disease.
(
- Contribution to journal › Letter
-
Mark
Prophylaxis in von Willebrand disease.
(
- Contribution to journal › Article
-
Mark
Why does the mutation G17736A/Val107Val (silent) in the F9 gene cause mild haemophilia B in five Swedish families?
(
- Contribution to journal › Article
-
Mark
Protecting the joints of mice and men.
(
- Contribution to journal › Article
-
Mark
Haemophilia in the first years of life.
(
- Contribution to journal › Article
-
Mark
Inhibitor development.
(
- Contribution to journal › Article
-
Mark
Asn1421Lys mutation in the glycoprotein Ib binding domain impairs - ristocetin and botrocetin - mediated binding of von Willebrand factor to platelets
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.116-116(
- Contribution to journal › Published meeting abstract
-
Mark
Venous access - why such diverse experiences of central venous lines?
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.96-96(
- Contribution to journal › Published meeting abstract
-
Mark
Management of delivery and neonatal period
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.5-5(
- Contribution to journal › Published meeting abstract
-
Mark
VWD type 3 - historical review and contemporary treatment dilemmas
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.111-111(
- Contribution to journal › Published meeting abstract
-
Mark
Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG)
(
- Contribution to journal › Article
-
Mark
Value added: increasing the power to assess treatment outcome in joint haemorrhages
(
- Contribution to journal › Article
-
Mark
Reliability and construct validity of the compatible MRI scoring system for evaluation of elbows in haemophilic children.
(
- Contribution to journal › Article
- 2007
-
Mark
Prevention of bleeding in haemophilia: trends, overcoming barriers and future treatment options
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
(
- Contribution to journal › Article
-
Mark
Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
-
Mark
VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
(
- Contribution to journal › Article
-
Mark
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
(
- Contribution to journal › Article
-
Mark
A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors
(
- Contribution to journal › Article
-
Mark
The economics of haemophilia prophylaxis; governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium.
(
- Contribution to journal › Article
- 2006
-
Mark
The 80th anniversary of von Willebrand's disease: history, management and research
(
- Contribution to journal › Scientific review
-
Mark
Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
(
- Contribution to journal › Article
-
Mark
Von Willebrand's disease: clinical management
(
- Contribution to journal › Article
-
Mark
Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia
(
- Contribution to journal › Article
-
Mark
Recent developments in clinimetric instruments
(
- Contribution to journal › Article
-
Mark
Pharmacoeconomics of factor dosing in the haemophilia population.
(
- Contribution to journal › Article
-
Mark
Practice patterns in haemophilia A therapy - global progress towards optimal care
(
- Contribution to journal › Article